Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Cannasouth secures R&D funding from Callaghan Innovation

The Board of Cannasouth Limited (NZX: CBD) is pleased to advise it has received confirmation of funding from Callaghan Innovation to support two of its medicinal cannabis research programmes, subject to completion of the formal contract.

Cannasouth applied for a project grant from the government-owned agency in March 2019 to fund research in the areas of Neuropathic Pain/Drug Discovery, and Drug Bioavailability/Delivery System/Optimisation Technology.

Callaghan has committed to contributing up to $347,008 (excl. GST) to the projects over the next three years. This is conditional on Cannasouth spending up to $566,172 (excl. GST) to match the projects funding.

Chief Operating Officer Nic Foreman says the proposed funding is essential to support the Company’s technical and commercialisation programmes.

“Securing capital to ensure we make timely progress in research is key to the commercial success of our therapeutic cannabinoids products.”

“This grant will allow us to take the next step towards the development of advanced cannabinoid formulations ready for human efficacy and drug delivery-controlled trials.”

Today’s announcement is in addition to three previous grants from Callaghan Innovation for projects that Cannasouth and its research partners have either completed or are underway.

“We are grateful to Callaghan for investing in the emerging medicinal cannabis sector,” says Foreman. “We are excited about the potential for our research to enhance outcomes for patients suffering from a wide range of debilitating medical conditions.”

Foreman confirms that the Callaghan Innovation funding will enable Cannasouth and its research partners to apply to the Ministry of Health (MoH) for the necessary licenses to conduct the research and development projects specified in the grant application.

Plant material from Cannasouth’s Waikato-based cultivation facility will be used in its Waikato Innovation Park laboratory to extract cannabinoid compounds for the proposed projects. The first harvest of plants growing in the facility is expected in the next two months.

Today’s funding announcement comes following Cannasouth’s oversubscribed Initial Public Offering (IPO) of new shares and subsequent listing of the Company on the NZX Main Board on 19 June 2019.

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 


Bell Gully: Uncertainty Ahead With New Unconscionable Conduct Legislation

new prohibition against ‘unconscionable conduct’ in trade is one of a number of changes to the Fair Trading Act 1986 that come into force from 16 August 2022. The new prohibition may have wide-ranging implications for many businesses... More>>


Statistics: Food Prices Increase 7.4 Percent Annually
Food prices were 7.4 percent higher in July 2022 compared with July 2021, Stats NZ said today... More>>



REINZ: Market Activity And Prices Continue To Ease, First Home Buyers Start To Return To The Market

New Zealand’s winter property market continues its recent trend, slowing from the pace of sales and price rises of last year — properties stay on the market longer and median prices dip... More>>



Kiwi Group Holdings: Fisher Funds Acquires Kiwi Wealth Business

Kiwi Group Holdings Limited (KGHL) today announced the sale of Kiwi Wealth to Fisher Funds for NZ$310 million... More>>



Retail NZ: Welcomes Return Of Cruise Ships

“Cruise visitors were big spenders in retail prior to COVID-19, and retailers in Auckland will be celebrating the arrival of P&O’s Pacific Explorer this morning... More>>



ASB: Full Year Results: Building Resilience Today And For Our Future

In its 175th year, ASB has reported a cash net profit after tax of $1,418 million for the 12 months to 30 June 2022, an increase of $122 million or 9% on the prior year... More>>